Floatz logo

Irinotecan

Genital Neoplasms, Female

GlaxoSmithKlineSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Genital Neoplasms, Female cohort.

Asset / SponsorPhaseRating
Carboplatin
Wenjun Cheng
Phase 3BB
Inno-206
Amgen
Phase 3BB
Cyclophosphamide
Sheba Medical Center
Phase 2B
Epirubicin
Sheba Medical Center
Phase 2B
Pembrolizumab
Sheba Medical Center
Phase 2B

View all 18 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →